155 related articles for article (PubMed ID: 34830702)
41. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
42. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis.
Yamazaki S; Ichimura S; Iwamoto J; Takeda T; Toyama Y
J Bone Miner Metab; 2004; 22(5):500-8. PubMed ID: 15316873
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
[TBL] [Abstract][Full Text] [Related]
44. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis.
Huang S; Lin H; Zhu X; Chen X; Fan L; Liu C
Endokrynol Pol; 2014; 65(2):96-104. PubMed ID: 24802732
[TBL] [Abstract][Full Text] [Related]
45. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
46. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
[TBL] [Abstract][Full Text] [Related]
47. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
Zhou W; Liu Y; Guo X; Yang H; Xu Y; Geng D
Osteoporos Int; 2019 Aug; 30(8):1581-1589. PubMed ID: 31115592
[TBL] [Abstract][Full Text] [Related]
48. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
[TBL] [Abstract][Full Text] [Related]
49. The role of zoledronic acid in the management of osteoporosis.
Maricic M
Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
[TBL] [Abstract][Full Text] [Related]
50. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
Nakamura T; Ito M; Hashimoto J; Shinomiya K; Asao Y; Katsumata K; Hagino H; Inoue T; Nakano T; Mizunuma H;
Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
[TBL] [Abstract][Full Text] [Related]
51. TRACP-5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia.
Ota I; Ota Y; Ota K; Eda H; Ohta H
JBMR Plus; 2022 Nov; 6(11):e10690. PubMed ID: 36398113
[TBL] [Abstract][Full Text] [Related]
52. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
[TBL] [Abstract][Full Text] [Related]
53. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
[TBL] [Abstract][Full Text] [Related]
54. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
Zheng WB; Dai Y; Hu J; Zhao DC; Wang O; Jiang Y; Xia WB; Xing XP; Li M
Endocr Pract; 2020 Dec; 26(12):1477-1485. PubMed ID: 33471740
[TBL] [Abstract][Full Text] [Related]
55. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
56. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
[TBL] [Abstract][Full Text] [Related]
57. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
58. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
[TBL] [Abstract][Full Text] [Related]
59. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
[TBL] [Abstract][Full Text] [Related]
60. Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs.
Glüer CC; Scholz-Ahrens KE; Helfenstein A; Delling G; Timm W; Açil Y; Barkmann R; Hassenpflug J; Stampa B; Bauss F; Schrezenmeir J
Bone; 2007 Mar; 40(3):645-55. PubMed ID: 17174621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
